Why Some Young People with Type 1 Diabetes Keep Making Insulin Years Later

In Type 1 diabetes, the immune system attacks the beta cells in the pancreas that produce insulin. However, not all beta cells are destroyed at once. In some people, a small number of these cells survive and continue producing some insulin years after diagnosis—a phenomenon called residual beta-cell function (RBCF).

Even small amounts of endogenous (body-made) insulin can have measurable health benefits, including better blood sugar stability and reduced risk of low blood sugar episodes. Understanding who keeps this residual function—and why—could help guide personalized diabetes care.

Researchers followed 72 children with Type 1 diabetes that had lasted at least 7 years. They measured how much C-peptide (a marker of insulin production) the children's pancreases were still making. About 30% of the children still had detectable residual function.

Two factors stood out as strong predictors of who kept their residual function: (1) children who had higher C-peptide levels at the time of their original diagnosis were more likely to preserve function long-term, and (2) children with shorter disease duration (fewer years since diagnosis) were more likely to retain some insulin production.

Interestingly, other factors that researchers expected to matter—including whether a child had ketoacidosis at onset, how many autoantibodies were present at diagnosis, or how well controlled their blood sugar has been—did not significantly affect long-term residual function.

This research adds to growing evidence that the loss of insulin-producing cells in Type 1 diabetes is not always a swift, complete process. In a meaningful minority of young people, some beta cells remain functional years into their disease.

The findings suggest that how much beta-cell function remains at diagnosis may be a clue to what will happen years later. This information could help clinicians identify which children might benefit most from interventions aimed at preserving remaining insulin production, though more research is needed to determine what those interventions should be.

As research into Type 1 diabetes continues to evolve, understanding residual beta-cell function remains one piece of a larger puzzle: how to slow or halt the autoimmune attack and protect the insulin-producing cells that remain.

Source: Journal of pediatric endocrinology & metabolism : JPEM. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.